Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opaganib +/- HCQ in Advanced Cholangiocarcinoma
NCT03377179Phase 2Completed
- Sponsor
- RedHill Biopharma
- Start
- Mar 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Opaganib in cholangiocarcinoma (CCA), sponsored by RedHill Biopharma. Started Mar 2018; status: completed.
02
Drugs
Opaganib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03377179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377179.